With so many therapeutics having to change primary endpoint, will leronlimab receive any special consideration for tackling the most challenging EP of them all? That is, will leronlimab be graded on a curve by the FDA? As a supporter, of course I feel they should get all due consideration, but for those that have experience with clinical trials, is this something an un-biased FDA would consider?